Introduction {#S1}
============

*Apolipoprotein-E* (*APOE*) and *angiotensin-1-converting enzyme* (*ACE*) polymorphisms have received a great deal of attention in relation to dementia risk (e.g. \[[@R1; @R2]\]). *APOE*, found on chromosome 19, is involved in lipid transport in the body \[[@R3]\]. There are three alleles---ε2, ε3, ε4---with ε3 being the most common \[[@R1]\]. *APOE* is associated with many neuropathological features of Alzheimer's disease (AD), the most common form of dementia, including plaque and tangle formation, β-amyloid deposition and cholinergic dysfunction (e.g. \[[@R4]\]). Two meta-analyses have reported that in population-based studies those with the ε4/ε4 genotype as compared to those with the ε3/ε3 are 12--13 times more likely to develop AD \[[@R1; @R5]\]. Results are less consistent regarding individual alleles, with not all population-based studies reporting that the ε4 allele confers a risk of AD/dementia or the ε2 allele a protective effect \[[@R6; @R7; @R8; @R9; @R10; @R11; @R12; @R13; @R14; @R15; @R16]\].

*ACE* appears to be involved in blood pressure regulation and electrolyte balance \[[@R17]\]. It is found on chromosome 17 and there are two allele types, D (a deletion) and I (an insertion), relating to intron 16. Neuropathological studies have been inconsistent as to whether *ACE* is associated with neuropathological features of AD (e.g. \[[@R18; @R19]\]). One recent meta-analysis of clinical/necropsy (i.e. non-population-based) samples reported that the D/D genotype conferred a protective effect on AD (odds ratio, OR = 0.8; 95% confidence interval, CI = 0.8--0.9), the I/D genotype a risk (OR = 1.1, 95% CI = 1.0--1.2) while the I/I had had no effect on AD---with referents being the combination of remaining genotypes \[[@R2]\]. Another meta-analysis on clinical/necropsy samples (i.e. not population-based) reported that the I allele conferred a 1.1 risk (95% CI = 1.0--1.2) for AD compared to the D allele; however, this association was non-significant when adjusting for Hardy--Weinberg equilibrium deviations and non-Caucasian ancestry \[[@R1]\]. There have been few population-based studies of *ACE* and of these they have generally reported no or small associations between the *ACE* polymorphism and AD \[[@R19; @R20; @R21]\].

As stated above, there is a great deal of evidence for *APOE* being associated with AD or dementia, and the evidence concerning *ACE* is not so consistent. Whether the effects and/or the sizes of such effects reported previously are relevant in a population context is uncertain. This is because the majority of previous research has been conducted on selected clinic/necropsy samples which do not represent the population most at risk of dementia. Accordingly, the current study aimed to assess incident late-onset dementia risk as conferred by *APOE* and *ACE* polymorphisms in a population-based sample with a long follow-up (10 years).

These analyses update previous analyses completed on the Medical Research Council Cognitive Function and Ageing Study (CFAS) sample in relation to *APOE* \[[@R22]\] and *ACE* \[[@R23]\]. This paper extends these analyses in that it includes another follow-up wave of data collection, increasing the follow-up time from 6 to 10 years which increases the number of incident dementia cases by around 60%. Results were weighted back to the original MRC CFAS sample, to fully take account of drop-out, which has recently become a standard technique. Notably, these previous papers on the MRC CFAS sample reported that the ε4 *APOE* allele conferred a small risk for all dementia \[[@R22]\] whilst the *ACE* polymorphism did not confer any dementia risk \[[@R23]\].

Methods {#S2}
=======

Sample {#S2-1}
------

MRC CFAS has been fully described in Brayne *et al.* \[[@R24]\] and will only be briefly described here. It is a large longitudinal population-based multi-centre study on ageing and dementia in England and Wales, with participants aged ≥65 at baseline. Sampling was based on geographical areas using general practitioner registration details. The initial response rate was 82%, and there has been a drop-out rate of 13--29% between follow-up waves due to death, moving away or refusal \[[@R25; @R26]\]. Four of the six study centres were used in these analyses: East Cambridgeshire, Gwynedd, Newcastle and Nottingham. The remaining two centres, Oxford and Liverpool, collected and analysed blood samples at different times and according to a different study protocol and are thus not included here.

In relation to the four centres included, there were 10,264 participants aged ≥65 years (stratified by equal numbers aged 65--74 and \>75) at baseline ('prevalence screen') beginning in 1991. The study employed a two-phase design, with a more comprehensive assessment given to a subsample (*n *= 2,034) at baseline ('prevalence assessment') stratified by age and cognitive function (biased toward those older and those with worse cognitive function). There have been multiple re-screens and re-assessments to detect incident dementia, of which the current study employs those at 2 (wave 2), 6 (wave 3) and 10 (wave 5) years. For this analysis, the 2-year follow-up included only those in the prevalence assessment subsample (*n *= 1,052), the 6-year follow-up included those in the prevalence assessment subsample and another subsample of those part of the incidence screen (*n *= 1,335), and the 10-year follow-up included all study participants still alive (*n *= 2,452). The MRC CFAS study design is illustrated in Figure [1](#F1){ref-type="fig"}.

![An illustration of the MRC CFAS study design and the number of participants seen at each screen/assessment relative to the four centres used in the current study. The grey shading indicates assessments that were used to define cases of incident dementia.](afp210fig1){#F1}

Blood or a buccal swab was collected at wave 3, 6 years into the study, with 62% (*n *= 1,070 or *n *= 945 excluding prevalent dementia at baseline) of participants who were included in the wave 3 interview consenting. It is these participants who consented to give genetic material that are included in these analyses. They had a mean age of 73.8 (SD = 6.5) at baseline; 60% women. Ethnic background was asked in a subset of the sample, of which 99% reported being of white British background.

Measures {#S2-2}
--------

A computer-automated version of the Geriatric Mental State known as the Automated Geriatric Examination for Computer Assisted Taxonomy (AGECAT) was used to assess the presence of dementia at interview by trained interviewers from professions allied to health. Those with an AGECAT organicity rating of O3 and above (score range 0--5) were classified as demented.

The Mini-Mental State Examination (MMSE) was used to obtain further evidence of cognitive impairment (score range from 0 to 30). The MMSE was employed to create two different control groups: 'non-demented' and 'highly functioning (HF) non-demented'. The non-demented group included participants not classified as demented (i.e. an AGECAT organicity rating of ≤O2). The HF non-demented group was not demented and also displayed no cognitive impairment, as defined as an MMSE of ≥26. By excluding those with an MMSE \<26, cases with mild cognitive impairment (MCI) or low baseline cognitive ability are mostly excluded. MCI is a prodrome of dementia that has been shown to predict conversion to dementia \[[@R27]\] and appears to relate to *APOE* status \[[@R28]\]. Thus, by excluding those with MCI, those cases most likely to convert to dementia are dropped. However, those with naturally low baseline cognitive abilities are also excluded when using this MMSE cut-off, which reduces the representativeness of the sample to the population. Control groups similar to the HF non-demented group are commonly employed in genetic studies, including those using the MRC CFAS sample \[[@R22; @R23]\]. However, the complete non-demented group most closely resembles the general population of individuals without dementia.

*APOE* and *ACE* genotyping was carried out in line with Wenham *et al.* \[[@R29]\] and Evans *et al.* \[[@R30]\], respectively, blind to clinical status. Ambiguous results were re-run up to three times, after which they were recorded as 'unknown'. *APOE* genotype was determined in 955 participants and *ACE* in 856 participants (excluding those with prevalent dementia at baseline).

Ethics statement {#S2-3}
----------------

MRC CFAS has multi-centre research ethics committee's approval and ethical approval from the relevant local research ethics committees.

Analysis {#S2-4}
--------

Logistic regression analyses were undertaken to examine the associations between *APOE*/*ACE* polymorphisms and incident dementia (with dementia as the outcome). Prevalent dementia cases at baseline were excluded from analyses as these participants who went on to consent to DNA collection 6 years later are atypical dementia cases in terms of length of illness without death. Incident dementia was assessed at 2, 6 and 10 years (corresponding to waves 2, 3 and 5, respectively). Analyses were adjusted for wave, age group at interview (65--74, 75--84, 85--94 and 95+), education (low education ≤9 and high education \>9 years) and social class. If education information was missing, it was coded as 'low education'. If social class information was missing, it was coded as 'social class missing'. *ACE* analyses were also adjusted for *APOE* genotype. Analyses were run relative to *APOE* and *ACE* genotype and allele status. The ε3 allele and ε3/ε3 genotype were employed as the reference groups in *APOE* analyses, and the D allele and I/D genotype were employed as the reference groups for *ACE*. Allelic analyses were undertaken with the assumption that the two alleles from each case were independent.

Each analysis was repeated with both control groups (non-demented and HF non-demented controls); however, analyses relating to the non-demented control group were focused on. Adjusted as well as adjusted and weighted results are presented. Back weighting was employed to provide a population estimate which takes into account the MRC CFAS sampling procedure and those who dropped out prior to the respective case finding interview. Those selected for the more comprehensive prevalence assessment were older and more likely to be cognitively impaired, though all cognitive abilities were represented. Further, those who dropped out were more likely to be cognitively impaired and older than those that did not \[[@R25]\]. Thus, both the sampling procedure and drop-outs influence the age of the sample. Given genetic associations with dementia, particularly with *APOE*, are stronger in the young as compared to the old \[[@R31]\]; not weighting back would most likely incorrectly estimate genetic associations.

Results {#S3}
=======

Table [1](#T1){ref-type="table"} displays the distribution of *APOE* and *ACE* genotypes and allele frequencies for cases and controls (both non-demented and HF non-demented) relative to 2-, 6- and 10-year follow-ups.

###### 

Distribution of *APOE* and *ACE* genotypes and allele frequencies for cases and controls (both non-demented and HF non-demented), relative to years 2, 6 and 10 (corresponding to waves 2, 3 and 5, respectively)

             2 years/wave 2   6 years/wave 3   10 years/wave 5                                                                                  
  ---------- ---------------- ---------------- ----------------- ---- ----- ---- ----- ---- ------- ---- ----- ---- ----- ---- ----- ---- ----- ----
  *APOE*                                                                                                                                        
  Allele                                                                                                                                        
  ε2         4                10               166               9    70    9    5     3    161     9    70    9    8     7    77    10   34    9
  ε3         28               70               1,471             79   639   78   114   78   1,357   79   595   77   77    71   616   79   290   80
  ε4         8                20               233               12   109   13   27    18   206     12   103   13   23    21   83    11   40    11
  Total      40                                1,870                  818        146        1,724        768        108        776        364   
                                                                                                                                                
  Genotype                                                                                                                                      
  ε2/ε2      0                0                7                 1    3     1    1     1    6       1    4     1    0     0    3     1    2     1
  ε2/ε3      3                15               128               14   55    13   2     3    126     15   55    14   7     13   62    16   27    15
  ε2/ε4      1                5                24                3    9     2    1     1    23      3    7     2    1     2    9     2    3     2
  ε3/ε3      11               55               583               62   251   61   46    63   537     62   229   60   26    48   244   63   114   63
  ε3/ε4      3                15               177               19   82    20   20    27   157     18   82    21   18    33   66    17   35    19
  ε4/ε4      2                10               16                2    9     2    3     4    13      2    7     2    2     4    4     1    1     1
  Total      20                                935                    409        73         862          384        54         388        182   
                                                                                                                                                
  *ACE*                                                                                                                                         
  Allele                                                                                                                                        
  I          20               50               838               50   365   49   64    53   773     50   341   48   51    53   349   50   165   48
  D          20               50               834               50   385   51   56    47   779     50   363   52   45    47   349   50   177   52
  Total      40                                1,672                  750        120        1,552        704        96         698        342   
                                                                                                                                                
  Genotype                                                                                                                                      
  D/D        7                35               227               27   107   29   15    25   213     27   104   30   11    23   98    28   49    29
  I/D        6                30               380               45   171   46   26    43   353     45   155   44   23    48   153   44   79    46
  I/I        7                35               229               27   97    26   19    32   210     27   93    26   14    29   98    28   43    25
  Total      20                                836                    375        60         776          352        48         349        171   

Table [2](#T2){ref-type="table"} displays the ORs and CIs---adjusted (for age group, sex, education and social class) as well as adjusted and weighted---for *APOE* genotype and allele status. It can be seen that the ε4 allele conferred a significant risk of dementia (OR = 2.9, 95% CI = 1.7--4.9) and the ε2 allele a significant protective effect (OR = 0.3, 95% CI = 0.1--0.6) relative to the non-demented control group (ε3 referent). Regarding *APOE* genotypes, the ε3/ε4 and ε4/ε4 genotypes conferred significant risks for dementia (OR = 3.6, 95% CI = 1.8--7.3 and OR = 7.9, 95% CI = 1.6--39.2, respectively) relative to the non-demented control group. The ε2/ε3 was associated with a decreased OR = 0.3 (95% CI = 0.1--0.7), with the ε2/ε2 genotype conferring a similar protective effect of OR = 0.3 with a wide 95% CI (0.1--1.7), though only one individual with ε2/ε2 had dementia. Allele and genotype effects were generally more extreme for the HF non-demented control group comparisons.

###### 

ORs and 95% CIs for associations between *APOE* allele/genotype and dementia

             Comparison using non-demented controls   Comparison using HF non-demented controls                                              
  ---------- ---------------------------------------- ------------------------------------------- ----- ----------- ----- ----------- ------ -----------
             OR                                       95% CI                                      OR    95% CI      OR    95% CI      OR     95% CI
  Allele                                                                                                                                     
  ε2         0.6                                      0.3--0.9                                    0.3   0.1--0.6    0.6   0.3--1.1    0.2    0.1--0.5
  ε3         1.0                                                                                  1.0               1.0               1.0    
  ε4         2.2                                      1.6--3.0                                    2.9   1.7--4.9    2.4   1.6--3.5    3.2    1.8--5.6
  Genotype                                                                                                                                   
  ε2/ε2      0.5                                      0.0--5.7                                    0.3   0.1--1.7    0.1   0.0--6.0    0.1    0.0--0.4
  ε2/ε3      0.6                                      0.3--1.1                                    0.2   0.1--0.7    0.7   0.3--1.4    0.3    0.1--0.8
  ε2/ε4      0.6                                      0.2--2.3                                    0.2   0.0--1.3    1.2   0.3--5.4    0.6    0.2--2.1
  ε3/ε3      1.0                                                                                  1.0               1.0               1.0    
  ε3/ε4      2.3                                      1.5--3.6                                    3.6   1.8--7.3    2.1   1.3--3.5    3.1    1.4--6.5
  ε4/ε4      5.0                                      1.9--13.0                                   7.9   1.6--39.2   9.1   3.0--27.2   18.1   4.9--67.0

For age group, sex, education and social class.

For study design and drop-out.

Table [3](#T3){ref-type="table"} displays the ORs and 95% CIs---adjusted (for age group, sex, education and social class) as well as adjusted and weighted---for *ACE* genotype and allele status. From Table [3](#T3){ref-type="table"}, it can be seen that the ACE I allele conferred a small dementia risk and the I/I and D/D genotypes a small degree of protection; however, all estimates are consistent with no effect.

###### 

ORs and 95% CIs for associations between *ACE* allele/genotype and dementia

             Comparison using non-demented controls   Comparison using HF non-demented controls                                           
  ---------- ---------------------------------------- ------------------------------------------- ----- ---------- ----- ---------- ----- ----------
             OR                                       95% CI                                      OR    95% CI     OR    95% CI     OR    95% CI
  Allele                                                                                                                                  
  I          0.9                                      0.7--1.2                                    1.1   0.5--2.3   1.2   0.9--1.6   1.3   0.8--2.2
  D          1.0                                                                                  1.0              1.0              1.0   
  Genotype                                                                                                                                
  I/I        0.9                                      0.6--1.4                                    0.5   0.3--1.0   0.9   0.6--1.4   0.5   0.3--1.0
  I/D        1.0                                                                                  1.0              1.0              1.0   
  D/D        1.2                                      0.8--1.8                                    0.8   0.5--1.4   1.2   0.8--1.8   0.8   0.5--1.4

For age group, sex, education, social class and *APOE* genotype.

For study design and drop-out.

Discussion {#S4}
==========

Dementia risk in the population is associated with *APOE* but not *ACE*. Effects were generally larger when employing the high functioning non-demented as compared to the total population of non-demented individuals. This is likely to be due to the exclusion of those with MCI who are at high risk of converting to dementia \[[@R27]\]. This finding suggests that highly selected control groups which are typically employed in genetic association studies are likely to lead to the overestimation of effect sizes, and their relevance to the population must be interpreted with caution. However, although effects were generally more extreme, 95% CIs from analyses employing either type of control group overlapped, which suggests a consistency in the direction of effects.

As expected, effects were also larger when they were weighted back to the original population sample, which accounted for the sampling procedure and drop-outs in the study, both of which influence the age of the sample. As introduced previously, *APOE* genotype affects age at dementia onset \[[@R31]\] and thus not weighting is likely to lead to incorrect estimates. This finding has important implications for future population-based genetic studies.

The study is not without limitations. Longitudinal follow-up studies have drop out between waves. However, the statistical method of back weighting accounted for any bias this along with attrition (due to drop-out) within the centres included may have introduced \[[@R25]\]. The AGECAT diagnostic algorithm was used to classify participants as demented or non-demented. Although it would have been preferential to have participants individually assessed by a clinician, this was not possible for such a large sample, and AGECAT classifications are closely related to diagnoses made by psychiatrists with the Diagnostic and Statistical Manual IIIR \[[@R32; @R33]\]. The study also assessed dementia in general rather than specific clinical diagnoses of AD, which adds weight to the relevance of findings to the population but does not provide information regarding risk relative to specific subtypes of dementia such as AD.

Results reinforce the importance of *APOE* alleles in terms of dementia risk in the population, with previous population-based studies being somewhat inconsistent \[[@R6; @R7; @R8; @R9; @R10; @R12]\], perhaps due to smaller sample sizes, the inclusion of prevalent dementia and/or short follow-up times. Regarding *APOE* genotype, the ε3/ε4 and ε4/ε4 genotypes were consistently associated with incident dementia risk---conferring four to eight times the risk (relative to the non-demented control group). This result is similar to two meta-analyses on population studies that reported the ε4/ε4 genotype was associated with 12--13 times greater AD risk \[[@R1; @R5]\]. There was a protective effect of the ε2/ε2 genotype which is similar to a meta-analysis by Farrer *et al.* \[[@R5]\] who reported the AD risk conferred by ε2/ε2 to be OR = 0.9 (95% CI = 0.3--2.8).

It is possible that those with an *APOE* ε2 allele died before being eligible for entry into the study, given their increased mortality at younger ages \[[@R34]\], and thus the protective effect found could be an artefact of survival. However, the impact of these effects is concerned with those who survive into the age when dementia becomes most prevalent, in old age. APOE results from this study are more extreme than those previously reported on the MRC CFAS sample \[[@R22]\] most likely due to the longer follow-up time and use of back weighting.

Previous studies have reported that the *ACE* I allele confers a risk for incident dementia \[[@R1]\] and that the I/I and D/D genotypes protect against dementia relative to the I/D genotype \[[@R2; @R19]\]. Our results were consistent, with small effects seen in these directions. This result is in line with small effect sizes or null results from population-based studies \[[@R19; @R20; @R21; @R23]\], suggesting that the ACE effect is at best weak.

Results from the current study reiterate the importance of *APOE* in relation to incident dementia risk in the population. The current study was large and addressed many of the methodological issues in previous population-based genetic association studies: long follow-up time, exclusion of prevalent dementia at baseline and weighting back to the original population. Differences between non-demented and HF non-demented control group comparisons also highlighted how control selection affects genetic association estimates.

It should be noted that despite the large sample size and long follow-up time it would still be desirable for these to be increased in future studies. Only around 20% of cases of incident dementia in the MRC CFAS sample displayed an ε4 allele (as compared to around 12% of the non-demented regardless of control group), so it remains neither necessary nor sufficient, supporting suggestions that many other environmental and biological (including genetic) factors are involved in the clinical manifestation of dementia. From these results, it does not appear that *ACE* substantially raises the risk of incident dementia.

Key points {#S5}
==========

-   *APOE* associated with incident dementia in the old.

-   *ACE* does not substantially raise the risk of incident dementia.

-   Control selection affects genetic association estimates.
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